Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.

about

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q38545768

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Incorporating traditional and ...... metastatic colorectal cancer.

@en

type

Item

label

Incorporating traditional and ...... metastatic colorectal cancer.

@en

prefLabel

Incorporating traditional and ...... metastatic colorectal cancer.

@en

P1476

Incorporating traditional and ...... f metastatic colorectal cancer

@en

P2093

Dipen Maru

http://www.w3.org/2001/XMLSchema#string

Jeanne Tie

http://www.w3.org/2001/XMLSchema#string

Michael Z Michael

http://www.w3.org/2001/XMLSchema#string

Paul Waring

http://www.w3.org/2001/XMLSchema#string

P2860

High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients

Comprehensive molecular characterization of human colon and rectal cancer

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

P304

1033-1048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737159.2015.1052797

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christos S Karapetis

P577

2015-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26166616

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

biomarker